TNF and cancer: Our results indicate that endogenous R-RAS2Q72L, but not wild-type R-RAS2, is also required for the proper engagement of a wide variety of general immune and inflammatory responses in cancer cells (TNFα, NFκB, IFN) that likely impact in both the innate and adaptive immune system cells.